Corporate Banner
Satellite Banner
Technology Networks Header
Friday, November 28, 2014
Technology Networks
 
Register | Sign in
Home Page > Posters
  Posters

In Vitro Potency of Chemically Modified siRNAs Against TNF-alpha
The execution of succesful RNAi experiments depends upon multiple factors: 1. Design and identification of effective and specific siRNA sites 2. Enhancement of pharmacocinetic properties 3. Delivery of siRNA. Therefore we have designed, prepared and functionality tested a variety of chemical modifications. These have been tested in HeLa cells to ascertain wether they influence RNAi inducing activity. We have chosen tumor necrosis factor (TNF-alpha) as a target.

Date Posted: 04/09/2008
ePosters.net Ref: EP


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
New Device Could Make Large Biological Circuits Practical
Innovation from MIT could allow many biological components to be connected to produce predictable effects.
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
New Test Developed at Dana-Farber/Brigham and Women's Cancer Center
Rapid Heme Panel - A high-tech genetic test that speeds treatment decisions for blood cancer patients.
Researchers Silence Leading Cancer-Causing Gene
A novel siRNA-based molecule successfully targets KRAS, a well-studied but hard to halt protein important for cancer development and metastasis.
Tumor Suppressor Also Inhibits Key Property Of Stem Cells
The retinoblastoma protein inhibits cancer by controlling cell division. Now, researchers have shown that it also binds to and inhibits genes necessary for pluripotency.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Next-Gen Melanoma Drug Excels in Lab Tests
Anti-cancer activity was reported in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733.
Study Identifying Cell of Origin for Large, Disfiguring Nerve Tumors
Lays groundwork for development of new therapies.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv